CompletedNot Applicable

Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus

Pakistan152 participantsStarted 2025-01-16

Plain-language summary

Brivaracetam is increasingly being studied in adult status epilepticus populations, evidence in pediatric patients remains sparse, with only limited case series and observational studies reporting favorable outcomes. This study aims at direct comparison between intravenous brivaracetam and levetiracetam in the acute management of pediatric status epilepticus.

Who can participate

Age range1 Month – 16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Either gender * Aged one month to 16 years * Presenting with status epilepticus Exclusion Criteria: * Previously received intravenous antiseizure medication for the current episode prior to presentation * Known hypersensitivity to study drugs * Hemodynamically unstable, requiring inotropic support before administration

What they're measuring

Cessation of seizures

Timeframe: 30 minutes

Trial details

NCT IDNCT07163572

SponsorMuhammad Aamir Latif

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-16

View on ClinicalTrials.gov More Status Epilepticus trials